Skip to main content

Laura Castillo Ribelles

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Laura Castillo Ribelles

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Malalties neurodegeneratives , Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Malalties neurodegeneratives , Marta González Sepúlveda, Malalties neurodegeneratives , Annabelle Parent, Daniela Samaniego Toro, Malalties neurodegeneratives
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 30/06/2026

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Sara Lucas del Pozo, Eddie Pradas Gracia, Guillem Pintos Morell, Laura Castillo Ribelles, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Demencia mixta por Alzheimer y enfermedad cerebrovascular: un estudio clínico y experimental.

IP: Maria Pilar Delgado Martínez
Collaborators: Francesc Pujadas Navinés, Olga Maisterra Santos, Laura Castillo Ribelles, Carles Lorenzo Bosquet, Antonio Palasi Franco, Montserrat Solé Piñol, Maria Belén Gutiérrez Iglesias, Jesús Pizarro Gonzálvez, Diana Liebana Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 134310
Reference: PI19/00217
Duration: 01/01/2020 - 30/06/2024

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

Related professionals

carmen oliver marcuello

carmen oliver marcuello

Research assistant
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Eunice Blanco Vazquez

Eunice Blanco Vazquez

Administration and Management
Multidisciplinary Nursing Research Group
Read more
Neus Bellera Gotarda

Neus Bellera Gotarda

Senior researcher
Cardiovascular Diseases
Read more
Inmaculada Jimenez Ariza

Inmaculada Jimenez Ariza

Gestió i Administració
Accounting and Revenue Unit
Finance Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.